Monoclonal Antibodies in Cancer Therapy.

Zahavi D, Weiner L. · 2020

Read Monoclonal Antibodies in Cancer Therapy. by Zahavi D, Weiner L. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7551545.txt.

Introduction

Zahavi and Weiner review monoclonal antibodies in cancer therapy. Antibody therapy now sits beside surgery, radiation and chemotherapy. Antibodies can hit tumor cells in direct ways.

They can also spark lasting anti-tumor immune responses. The review covers known modes of action in patients. It sets out current clinical uses across cancers. Resistance pathways that limit benefit are discussed. New plans target immune cells rather than tumor markers. Combination plans pair antibodies with other treatments. Readers get a full picture of a central cancer platform. The authors show how the field is shifting toward immune activation.

Catalog record

CREATORZahavi D, Weiner L.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7551545

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Monoclonal Antibodies in Cancer Therapy By David Zahavi, Louis Weiner Published in: Antibodies DOI: 10.3390/antib9030034 ABSTRACT Abstract Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In addition, antibodies can directly target tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. The multifaceted properties of antibodies as a therapeutic platform have led to the development of new cancer treatment strategies that will have major impacts on cancer care. This review focuses on the known mechanisms of action, current clinical applications for the treatment of cancer, and mechanisms of resistance of monoclonal antibody therapy. We further discuss how monoclonal antibody-based strategies have moved towards enhancing anti-tumor immune responses by targeting immune cells instead of tumor antigens as well as some of the current combination therapies. Keywords: monoclonal antibody, cancer, immunology, antibody-dependent cellular cytotoxicity (ADCC), immune checkpoint blockade (ICB) 1. INTRODUCTION Antibodies were first described as a neutralizing substance found in blood by Behring and Shibasaburo in 1890 in their work on animal models of diphtheria [1]. Over the next century several important scientific advances would pave the way for the use of antibodies as a cancer therapeutic. Antibodies were identified as proteins that could recognize specific antigens by Heidelberger and Avery, and in 1947 Astrid Fagraeus demonstrated that antibodies were produced by plasma B cells of the adaptive immune system [2,3]. Sir Gustav Nossal then proved the clonal selection theory that a single B cell clone produces one specific antibody [4]. Thus, monoclonal antibodies (mAbs) are antibodies made by clones of a unique B cell, all of which bind to specific portions of an antigen also known as an epitope. Methods to produce monoclonal antibodies involving human–mouse hybrid cells were first identified by Schwaber in 1973 and were used by Köhler and Milstein to generate the human-derived hybridomas that have since been a mainstay in the large scale production of therapeutic antibodies [5,6]. Soon after the discovery of hybridomas, research into the use of mAbs to treat cancer began. Anti-melanoma mAbs were shown to suppress the growth of human melanomas in nude mice and in 1980 the first human trial of mAb therapy against cancer was conducted in a lymphoma patient [7,8]. Unfortunately, due to the murine origins of early therapeutic monoclonal antibodies, these mAbs were immunogenic in humans and were poor inducers of immunity in patients, thereby limiting their clinical applicability. In the late 1980s, techniques emerged to humanize antibodies in order to eliminate these limitations [9]. Further advances have led to the derivation of “fully-human” antibodies using transgenic mice or in vitro yeast or phage display systems [10,11]. As a result of these antibody engineering innovations, mAbs have become an important modality in the treatment of cancer. Antibodies are unique in their ability to both directly kill tumor cells while simultaneously engage the host immune system to develop long-lasting effector responses against the tumor. The combination of a multifaceted mechanism of action with target specificity distinguishes mAb therapy from treatments such as chemotherapy and underlies the capability of antibodies to elicit strong anti-tumor responses while minimizing toxicity and adverse events. To better understand how monoclonal antibodies function as a cancer therapy, we review their structure, mechanisms of action, clinical uses, mechanisms of resistance, and some combination strategies. 2. ANTIBODY STRUCTURE AND FUNCTION Antibodies are large glycoproteins that belong to the immunoglobulin (Ig) superfamily and their role in the immune system is to recognize foreign antigens, neutralize them, and elicit a further immune response. Their basic structure is composed of two heavy and two light chains in the shape of a Y. At each tip of the Y lies the fragment antigen-binding (Fab) portion of the antibody which is responsible for recognition of the specific antigen. The fragment crystallizable (Fc) region located at the base of the Y structure mediates interactions between the antibody and other members of the immune system [12]. Antibody Fc regions are recognized by Fc receptors (FcRs) found on a wide range of immune cells. Based on the type of heavy chain, antibodies can be separated into five distinct classes: IgA, IgD, IgE, IgG, and IgM. IgG is the most often form used in antibody therapy due to the fact that IgGs interact with their associated type of FcR, FcγR, found on natural killer (NK) cells as well as neutrophils, monocytes, dendritic cells, and eosinophils to mediate specialized functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The IgG class can further be subdivided based on the ability of the Fc region to facilitate those functions: IgG1 and IgG3 are able to elicit ADCC and CDC, while IgG2 and IgG4 cannot [13]. Monoclonal antibodies represent a clonal version of a specified antibody isotype that is targeted to a unique antigen epitope. 3. EFFECTOR MECHANISMS OF TARGETED MABS Targeted mAbs against antigens either unique to or overexpressed by tumor cells can cause tumor cell death by a variety mechanisms (Figure 1). The main direct mechanism by which many antibodies induce tumor cell death is the blockade of growth factor receptor signaling. Pro-tumor growth and survival signaling is perturbed when mAbs bind their target growth factor receptors and manipulate their activation state or block ligand binding. For example, epidermal growth factor receptor (EGFR) is overexpressed by many different cancers and signaling via EGFR leads to tumor cell proliferation, migration, and invasion. Cetuximab, which is an anti-EGFR mAb, induces apoptosis in tumor cells by blocking ligand binding and receptor dimerization [14,15]. Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that is overexpressed in many cancers but primarily ovarian and breast carcinomas [16]. It is distinct from EGFR in that it has no known ligand and instead hetero-dimerizes with other growth factor receptors to enhance their activation [17]. Antibodies targeting HER2 therefore achieve signaling perturbation by inhibiting hetero-dimerization and internalization. Trastuzumab was the first FDA approved anti-HER2 mAb and remains a vital component of treatments for HER2-amplified breast cancer. Indirect mechanisms of action of mAbs require the engagement of components of the host immune system and are CDC, antibody-dependent cellular phagocytosis (ADCP), and ADCC. Most targeted mAbs are able to activate the complement system. For instance, rituximab depends in part on CDC for its in vivo efficacy. In a preclinical model, rituximab anti-tumor effects were completely abolished by knockout of the complement cascade component C1q [18]. The importance of CDC in mAb therapy is further supported by the fact that genetic polymorphisms in the C1qA gene correlate with clinical response to rituximab in patients with follicular lymphoma [19]. Likewise, optimization of CDC via antibody engineering can enhance anti-tumor activity. For example, the anti-CD20 mAb ofatumumab, which mediates amplified CDC, demonstrated greater efficacy than rituximab in a clinical trial of chronic lymphocytic leukemia (CLL) patients [20]. ADCP occurs when FcγRI expressed on cells such as macrophages binds to IgG1 or IgG3 mAbs that have opsonized a tumor cell. There have been very limited studies of ADCP; however, there is some evidence that ADCP plays an important role in destruction of circulating tumor cells following mAb therapy [21]. First described in

Read the complete text